• Genentech Builds Single Cell Proteomics Platform for Real Time Mass Spec Analysis

    Bio-IT World | Our technical capabilities are becoming increasingly granular, and proteomics is no exception. At the recent Molecular & Precision Med TRI-CON, Christopher Rose reported on how his group within the Microchemistry, Proteomics & Lipidomics department at Genentech where he currently leads the Discovery Proteomics group is working to build a single-cell proteomics platform.

    Mar 3, 2022

  • Cloud IT, Structural Variants, AI for Cancer, More

    Bio-IT World | Structural variant detection in FFPE samples, new federated network for genomic variant surveillance, Element Biosciences’ new acquisitions and collaborations, RNA profiling to predict preterm birth, release of multi-modal mental health dataset, AI in genetic variant analysis for cancer and beta-propeller protein-associated neurodegeneration, and more.

    Mar 2, 2022

  • Follow the Money: ML in Immunology, Virtual Drug Screening; Single-Cell Multi-Omic Sequencing; AI Marketplace

    Bio-IT World | AI and ML in immunological therapeutic development, virtual drug screening, microscope-based rapid pathogen diagnostics, improved genetic variant interpretation, and more.

    Feb 28, 2022

  • IDMP as a Tool for Better Organizational Data

    Bio-IT World | The clock is ticking on implementing the EMA's IDMP standard. With the release of EU IG v2.1, the industry is in the final stages of preparations for optional submission. While regulatory teams have made progress applying guidance to uniquely identify products and standardize information, more work remains to establish a proper data foundation that supports submissions under the new requirements.

    Feb 25, 2022

  • Expert Panel: Next Steps to Achieving Precision Medicine

    Bio-IT World | In the opening plenary panel for the Molecular and Precision Med Tri-Con this week, Robert Green, Brigham and Women’s Hospital, led a group in exploring how genomics, digital health, and more will converge to deliver precision health. He was joined by Megan Mahoney, Stanford University; Jessica Mega, Verily Life Sciences; Sir Mark Caulfield, Barts Life Sciences & Queen Mary University of London; and Lara Jehi, Cleveland Clinic.

    Feb 24, 2022

  • Bring Spatial Techniques to Understanding Alzheimer’s Disease Pathology

    Bio-IT World | At this week’s Molecular & Precision Medicine Tri-Con event, Simon Gregory, profession or neurology at the Duke University School of Medicine, outlined how his team has been using 10X Genomics’ Visium platform and Oxford Nanopore long read sequencing to understand the pathology of Alzheimer’s Disease development.

    Feb 23, 2022

  • New Tools for Achieving MRD Detection, Accuracy

    Bio-IT World | On the first morning of the Molecular & Precision Med Tri-Con event, Viktor Adalsteinsson, associate director of the Gerstner Center for Cancer Diagnostics at the Broad Institute, explored new tools and techniques for detecting minimal residual disease.

    Feb 23, 2022

  • Launching a New Trends from the Trenches Podcast

    Bio-IT World | Bio-IT World and BioTeam have been exploring the drivers of life sciences innovation for years during the Bio-IT World Conference & Expo and in regular columns in the publication. Now, together, we’ve launched a new podcast to capture in-depth conversations with leaders in the field about data, culture, technology, and more.

    Feb 22, 2022

  • Why R? The Next Generation in Pharma

    Bio-IT World | All industries drive innovation. The pharmaceutical industry is no different — except that their innovations improve or save lives. The clinical trial process is an important activity that any drug or medical device company works with daily. This is often a target for innovations so that they can improve activities within the trial process. For years, the industry has been dominated by SAS software for its statistical and clinical reporting. Organizations are now actively starting to use other technologies with the R language being heavily adopted.

    Feb 18, 2022

  • Pistoia Alliance Plans Microbiome Atlas

    Bio-IT World | The Pistoia Alliance launched a new project on the microbiome yesterday, which could help speed up the advancement of new, precision medicines and treatments. The project is funded by Bayer, BMS, Eagle Genomics, Pfizer, Roche and Takeda and aims to incorporate microbiome data into the drug development pipeline by gathering all existing microbiome data to create a global standardized ‘atlas’ that scientists can refer to when choosing new drug candidates.

    Feb 17, 2022

  • NIH Sleep Research Plan Highlights Women’s Health, Reducing Disparities

    Bio-IT World | In December the National Institutes of Health (NIH) released the latest version if its Sleep Research Plan that used a crowdsourcing campaign to ensure all willing voices on the topic were captured. The congressionally-mandated plan, the fourth in a series published since 1996, seeks to draw the attention of investigators to high-priority areas that could “make an impact within the next five to 10 years,” according to Marishka K. Brown, Ph.D., director of the National Center on Sleep Disorders Research (NCSDR).

    Feb 15, 2022

  • GIAB Establishes New Benchmark for Several Medically Relevant, Difficult-to-Sequence Genes

    Bio-IT World |The Genome in a Bottle (GIAB) Consortium has just reported a new, expanded benchmark for 273 medically relevant genes that are challenging to clinically assess with current sequencing methods. The work is published in Nature Biotechnology.

    Feb 14, 2022

  • ‘Immune Archetypes’ Of Cancer Could Help Tailor Treatments To Tumors

    Bio-IT World | Immunotherapies vary widely in their ability to effectively treat patients with cancer, and the reason is the differing immune states of their tumor. Only a finite number of “immune archetypes” exist across all cancers—and these distinct environments are inhabited by more than the T cells targeted by currently marketed immunotherapy drugs.

    Feb 10, 2022

  • Releasing the Potential of Biobatteries

    Bio-IT World | Imagine batteries made from completely safe, organic, non-combustible, and biodegradable materials. Now imagine that these batteries can be recharged not from an outlet, but from the excess energy of our bodies. Refueling by gathering kinetic energy from our movement, or thermal energy from body heat, or—in what might be the most sci-fi scenario—feeding on the biochemical surplus of sugars coursing through our veins, or even compounds present in our saliva, sweat, or other body fluids. This idea is the biobattery, and the potential uses and benefits are pretty remarkable.

    Feb 9, 2022

  • Follow the Money: AI in Gastroenterology Research, Cloud Infrastructure Provisioning

    Bio-IT World | Sanofi and Exscientia collaborate to use AI for oncology and immunology treatments, Iterative Scopes using AI in gastroenterology treatments, Quris uses AI for clinical prediction, and more.

    Feb 8, 2022

  • Driving Value in Biopharma R&D through Digital Transformation

    Bio-IT World | Rapid scientific innovation is dependent on streamlining three key capabilities: improving data usability, enabling global cross-team collaboration, and automating scientific workflows. We believe that digital technologies should serve as the foundation that connects your data, people, and processes together to drive scientific discovery. From our perspective, the companies that embrace digital will ultimately win the R&D race.

    Feb 4, 2022

  • New Collaborations to Address Skin Care, Gastrointestinal Disease, MS, Whole-Cell Models, Spatial Genomics

    Bio-IT World | Skin health, particle-scale whole-cell models with NVIDIA, single-cell spatial genomics, diabetic kidney disease. Plus: AI in MS, inflammatory bowel disease, clinical trials, and genomic searches, and more.

    Feb 2, 2022

  • Novel CAR T Cells Give Cancer A One-Two Punch

    Bio-IT World | In an entirely new direction for immunotherapy, researchers at the Sloan Kettering Institute (SKI) have genetically engineered chimeric antigen receptor (CAR) T cells to produce potentially synergistic, small-molecule drugs that can penetrate a solid tumor.

    Feb 1, 2022

  • Illumina, Invitae Founding Members of ASHG’s Genetics and Genomics Impact Partnerships Program

    Bio-IT World | The American Society of Human Genetics (ASHG) today announced the launch of the ASHG Genetics and Genomics Impact Partnerships program. Illumina, a leader in next-generation genomic sequencing technologies, and Invitae, a leading medical genetics company, have joined as founding partners.

    Jan 31, 2022

  • Predicting COVID-19 Severity: Researchers Look to Fill Diagnostic Gap, Match Patients with Treatments

    Bio-IT World | Researchers at Mount Sinai and the University of Colorado are pursuing the possibilities that stem from predicting which COVID-19 patients are most likely to deteriorate over time. The hope is that this ability could help health care professionals more effectively triage patients and pair them with appropriate treatments to improve outcomes.

    Jan 27, 2022